Behavioral and Biochemical Effects of Amperozide and Serotonin Agents on Nigrostriatal and Mesolimbic Dopamine Systems

Pu-Yuan Chang；Chia-Hsin Chuang；Jin-Chung Chen；Che-Se Tung

amperozide ； 5-HT2 antagonism ； dopamine transporter blocker ； caudate putamen ； nucleus accumbens

The Chinese Journal of Physiology

51卷2期（2008 / 04 / 01）

106 - 115

英文

Central dopaminergic system serves two major physiological functions, i.e., motivation activation and motor coordination. The evidence that serotonergic system could modulate these two pathways suggests that serotonin (5-HT) and related agents may possess potential therapeutic values against certain mental or motor disorders caused by dopamine malfunction. This study presents novel modulatory role for serotonergic agents in rat behaviors which have been speculated to be associated with forebrain dopamine system. Three serotonergic agents, including DOI (5-HT2 agonist), ritanserin (5-HT2 antagonist) and amperozide (5-HT2/ D2 antagonist) were evaluated, focused particularly on the atypical antipsychotic amperozide. It was found that both amperozide and ritanserin could inhibit amphetamine-induced hyperlocomotion, and only amperozide inhibited nomifensine-induced hyperlocomotion. Amperozide could also reduce significantly the rearing but not sniffing behaviors. Further, DOI and amperozide, but not ritanserin, reduced the haloperidol-induced catalepsy. When animals were unilaterally radiofrequency lesioned in either caudate putamen (CP) or nucleus accumbens (NA), amperozide reduced both the ipsiand contralateral turns in CP-lesioned, but reduced only ipsilateral turns in NA-lesioned rats. Via in vivo microdialysis, we demonstrated that amperozide could increase the extracellular dopamine release in both CP and NA in either intact or para-chlorophenylalanine (p-CPA) serotonin-depleted rats. Overall, we conclude that the modulatory role of amperozide on forebrain dopamine system requires not only 5-HT2/D2 antagonistic but also the blockade of dopamine transporter.

1. Arnt, J.(1995).Differential effects of classical and newer antipsychotics on the hypermotility induced by two dose levels of D-amphetamine.Eur. J. Pharmacol.,283,55-62.
2. Arolfo, M.P.,McMillen, B.A.(1999).Effects of amperozide and tiospirone, atypical antipsychotic 5-HT2 drugs, on food-reinforced behavior in rats.Physiol. Behav.,68,93-98.
3. Bjork, A,Olsson, N.G.,Christensson, E.,Martinsson, K.,Olsson, O.(1988).Effects of amperozide on biting behavior and performance in restricted-fed pigs following regrouping.J. Anim. Sci.,66,669-675.
4. Bowers, B.J.,Henry, M.B.,Thielen, R.J.,McBride, W.J.(2000).Serotonin 5-HT (2) receptor stimulation of dopamine release in the posterior but not anterior nucleus accumbens of the rat.J. Neurochem.,75,1625-1633.
5. Christensson, E.G.(1990).Effects of amperozide on induced turning behaviour in 6-OHDA lesioned rats.Pharmacol. Toxicol.,66,22-28.
6. Cobb, W.S.,Abercrombie, E.D.(2003).Differential regulation of somatodendritic and nerve terminal dopamine release by serotonergic innervation of substantia nigra.J. Neurochem.,84,576-584.
7. Costall, B.,Fortune, D.H.,Hui, S.C.,Naylor, R.J.(1980).Neuroleptic antagonism of the motor inhibitory effects of apomorphine within the nucleus accumbens: drug interaction at presynaptic receptors?.Eur. J. Pharmacol.,63,347-358.
8. Costall, B.,Naylor, R.J.(1973).The role of telencephalic dopaminergic systems in the mediation of apomorphine-stereotyped behaviour.Eur. J. Pharmacol.,24,8-24.
9. Cragg, S.J.,Greenfield, S.A.(1997).Differential autoreceptor control of somatodendritic and axon terminal dopamine release in substantia nigra, ventral tegmental area, and striatum.J. Neurosci.,17,5738-5746.
10. Crocker, A.D.,Hemsley, K.M.(2001).An animal model of extrapyramidal side effects induced by antipsychotic drugs: relationship with D2 dopamine receptor occupancy.Prog. Neuropsychopharmacol. Biol. Psychiatry,25,573-590.
11. Dewey, S.L.,Smith, G.S.,Logan, J.,Alexoff, D.,Ding, Y.S.,King, P.,Pappas, N.,Brodie, J.D. and Ashby, C.R.(1995).Serotonergic modulation of striatal dopamine measured with positron emission tomography (PET) and in vivo microdialysis.J. Neurosci.,15,821-829.
12. Egbe, P.,Engel, J.,Gustafsson, B.,Christensson, E.(1990).Amperozide and conditioned behaviour in rats: potentiation by classical neuroleptics and alpha-methylparatyrosine.Pharmacol. Toxicol.,66,18-21.
13. Egbe, P.C.(1989).Locomotor effects of amperozide. Antagonism of amphetamine-induced locomotor stimulation.Arzneimittelforschung,39,1223-1224.
14. Eriksson, E.(1990).Amperozide, a putative anti-psychotic drug: uptake inhibition and release of dopamine in vitro in the rat brain.Life Sci.,47,2111-2117.
15. Eriksson, E.,Christensson, E.(1990).The effect of amperozide on uptake and release of [3H]-dopamine in vitro from perfused rat striatal and limbic brain areas.Pharmacol. Toxicol.,66,45-48.
16. Fredriksson, A.,Archer, T.(2002).Functional alteration by NMDA antagonist: effects of L-Dopa, neuroleptics drug and postnatal administration.Amino Acids,23,111-132.
17. Garris, P.A.,Budygin, E.A.,Phillips, P.E.,Venton, B.J.,Robinson, D.L.,Bergstrom, B.P.,Rebec, G.V.,Wightman, R.M.(2003).A role for presynaptic mechanisms in the actions of nomifensine and haloperidol.Neuroscience,118,819-829.
18. Gonyou, H.W.,Parfet, K.A.,Anderson, D.B.,Olson, R.D.(1988).Effects of amperozide and azaperone on aggression and productivity of growing-finishing pigs.J. Anim. Sci.,66,2856-2864.
19. Gulley, J.M.,Everett, C.V.,Zahniser, N.R.(2007).Inbred Lewis and Fischer 344 rat strains differ not only in novelty-and amphetamine-induced behaviors, but also in dopamine transporter activity in vivo.Brain Res.,1151,32-45.
20. Gustafsson, B.,Christensson, E.(1990).Amperozide-a new putatively antipsychotic drug with a limbic mode of action on dopamine mediated behaviour.Pharmacol. Toxicol.,66,12-17.
21. Gustafsson, B.,Christensson, E.(1990).Amperozide and emotional behaviour.Pharmacol. Toxicol.,66,34-39.
22. Hery, F.,Soubrie, P.,Bourgoin, S.,Motastruc, J.L.,Artaud, F.,Glowinski, J.(1980).Dopamine released from dendrites in the substantia nigra controls the nigral and striatal release of serotonin.Brain Res.,193,143-151.
23. Hicks, P.B.(1990).The effect of serotonergic agents on haloperidol-linduced catalepsy.Life Sci.,47,1609-1615.
24. Ichikawa, J.,Meltzer, H.Y.(2000).The effect of serotonin (1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens.Brain Res.,858,252-263.
25. Ichikawa, J.,Meltzer, H.Y.(1992).Amperozide, a novel antipsychotic drug, inhibits the ability of d-amphetamine to increase dopamine release in vivo in rat striatum and nucleus accumbens.J. Neurochem.,58,2285-2291.
26. Jimenez-Castellanos, J.,Graybiel, A.M.(1987).Subdivisions of the dopamine-containing A8-A9-A10 complex identified by their differential mesostriatal innervations of striosomes and extrastriosomal matrix.Neuroscience,23,223-242.
27. Jones, S.R.,Gainetdinov, R.R.,Wightman, R.M.,Caron, M.G.(1998).Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter.J. Neurosci.,18,1979-1986.
28. Jones, S.R.,Joseph, J.D.,Barak, L.S.,Caron, M.G.,Wightman, R.M.(1999).Dopamine neuronal transport kinetics and effects of amphetamine.J. Neurochem.,73,2406-2414.
29. Joyce, E.M.,Iversen, S.D.(1984).Dissociable effects of 6-OHDA-induced lesions of neostriatum on anorexia, locomotor activity and stereotypy: the role of behavioural competition.Psychopharmacology (Berl),83,363-366.
30. Joyce, E.M.,Stinus, L.,Iversen, S.D.(1983).Effect of injections of 6-OHDA into either nucleus accumbens septi or frontal cortex on spontaneous and drug-induced activity.Neuropharmacology,22,1141-1145.
31. Kapur, S.,Remington, G.(1996).Serotonin-dopamine interaction and its relevance to schizophrenia.Am. J. Psychiatry,153,466-476.
32. Kelly, P.H.,Seviour, P.W.,Iversen, S.D.(1975).Amphetamine and apomorphine responses in the rat following 6-OHDA lesions of the nucleus accumbens septi and corpus striatum.Brain Res.,94,507-522.
33. Kuroki, T.,Meltzer, H.Y.,Ichikawa, J.(1999).Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens.J. Pharmacol. Exp. Ther.,288,774-781.
34. Lacey, M.G.,Mercuri, N.B.,North, R.A.(1987).Dopamine acts on D2 receptors to increase potassium conductance in neurones of the rat substantia nigra zona compacta.J. Physiol.,392,397-416.
35. Lopez, S.,Turle-Lorenzo, N.,Acher, F.,De Leonibus, E.,Mele, A.,Amalric, M.(2007).Targeting group III metabotropic glutamate receptors produces complex behavioral effects in rodent models of Parkinson`s disease.J. Neurosci.,27,6701-6711.
36. Lucas, G.,Bonhomme, N.,De Deurwaerdere, P.,Le Moal, M.,Spampinato, U.(1997).8-OH-DPAT, a 5-HT1A agonist and ritanserin, a 5-HT2A/C antagonist, reverse haloperidol-induced catalepsy in rats independently of striatal dopamine release.Psychopharmacology (Berl),131,57-63.
37. Lucas, G.,Spampinato, U.(2003).Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications.Br. J. Pharmacol.,140,520-526.
38. Lucas, G.,Spampinato, U.(2000).Role of striatal serotonin2A and serotonin2C receptor subtypes in the control of in vivo dopamine outflow in the rat striatum.J. Neurochem.,74,693-701.
39. McMillen, B.A.,Jones, E.A.,Hill, L.J.,Williams, H.L.,Bjork, A.,Myers, R.D.(1993).Amperozide, a 5-HT2 antagonist, attenuates craving for cocaine by rats.Pharmacol. Biochem. Behav.,46,125-129.
40. McMillen, B.A.,Walter, S.,Williams, H.L.,Myers, R.D.(1994).Comparison of the action of the 5-HT2 antagonists amperozide and trazodone on preference for alcohol in rats.Alcohol,11,203-206.
41. Meltzer, H.,den Boer, J.A.,van Praag, W. H.M. (edited)(1995).Advances in the Neurobiology of Schizophrenia.London:Wiley and Sons.
42. Millan, M.J.,Brocco, M.,Gobert, A.,Joly, F.,Bervoets, K.,Rivet, J.,Newman-Tancredi, A.,Audinot, V.,Maurel, S.(1999).Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat.Eur. J. Neurosci.,11,4419-4432.
43. Mori, S.,Matsuura, T.,Takino, T.,Sano, Y.(1987).Light and electron microscopic immunohistochemical studies of serotonin nerve fibers in the substantia nigra of the rat, cat and monkey.Anat. Embryol. (Berl),176,13-18.
44. Myers, R.D.,Lankford, M.,Bjork, A.(1992).Selective reduction by the 5-HT antagonist amperozide of alcohol preference induced in rats by systemic cyanamide.Pharmacol. Biochem. Behav.,43,661-667.
45. Nagahiro, S.,Diksic, M.,Yamamoto, Y.L.,Riml, H.(1990).Noninvasive in-vivo autoradiographic method to measure axonal transport in serotoninergic neurons in the rat brain.Brain Res.,506,120-128.
46. Ossowska, K.(2002).Neuronal basis of neuroleptic-induced extrapyramidal side effects.Pol. J. Pharmacol.,54,299-312.
47. Overstreet, D.H.,Rezvani, A.H.,Cowen, M.,Chen, F.,Lawrence, A.J.(2006).Modulation of high alcohol drinking in the inbred Fawn-Hooded (FH/Wjd) rat strain: implications for treatment.Addict. Biol.,11,356-373.
48. Paxinos, G.,Watson, C.(1996).The Rat Brain in Stereotaxic Coordinates.San Diego:Academic Press.
49. Pettersson, E.(1995).Studies of four novel diphenylbutylpiper-azinepyridyl derivatives on release and inhibition of reuptake of dopamine, serotonin and noradrenaline by rat brain in vitro.Eur. J. Pharmacol.,282,131-135.
50. Pires, J.G.,Costa, P.G.,Saraiva, F.P.,Bonikovski, V.,Futuro Neto, H.A.(2003).Gender-related differences in the effects of nitric oxide donors on neuroleptic-induced catalepsy in mice.Braz. J. Med. Biol. Res.,36,239-245.
51. Silva, S.R.,Futuro-Neto, H.A.,Pires, J.G.(1995).Effects of 5-HT3 receptor antagonists on neuroleptic-induced catalepsy in mice.Neuropharmacology,34,97-99.
52. Sorensen, S.M.,Kehne, J.H.,Fadayel, G.M.,Humphreys, T.M.,Ketteler, H.J.,Sullivan, C.K.,Taylor, V.L.,Schmidt, C.J.(1993).Characterization of the 5-HT2 receptor antagonist MDL 100907 as a putative atypical antipsychotic: behavioral, electrophysiological and neurochemical studies.J. Pharmacol. Exp. Ther.,266,684-691.
53. Steinpreis, R.E.,Moser, L.,Parret, F.,Rutell, E.,Panos, J.(1998).The effects of the atypical antipsychotic amperozide on vacuous jaw movements in rats: a novel dose response profile.Psychopharmacology (Berl),138,107-113.
54. Sulzer, D.,Chen, T.K.,Lau, Y.Y.,Kristensen, H.,Rayport, S.,Ewing, A.(1995).Amphetamine redistributes dopamine from synaptic vesicles to the cytosol and promotes reverse transport.J. Neurosci,15,4102-4108.
55. Svartengren, J.,Celander, M.(1994).The limbic functional selectivity of amperozide is not mediated by dopamine D2 receptors as assessed by in vitro and in vivo binding.Eur. J. Pharmacol.,254,73-81.
56. Svartengren, J.,Pettersson, E.,Bjork, A.(1997).Interaction of the novel antipsychotic drug amperozide and its metabolite FG5620 with central nervous system receptors and monoamine uptake sites: relation to behavioral and clinical effects.Biol. Psychiatry,42,247-259.
57. Svartengren, J.,Simonsson, P.(1990).Receptor binding properties of amperozide.Pharmacol. Toxicol.,66,8-11.
58. Svartengren, J.O.(1993).Selective down-regulation of the agonist-dependent high affinity state of rat cortical 5-HT2 receptors following chronic treatment with amperozide.J. Recept. Res.,13,379-392.
59. Trent, F.,Tepper, J.M.(1991).Dorsal raphe stimulation modifies striatal-evoked antidromic invasion of nigral dopaminergic neurons in vivo.Exp. Brain Res.,84,620-630.
60. Ungerstedt, U.(1971).Stereotaxic mapping of the monoamine pathways in the rat brain.Acta. Physiol. Scand. Suppl.,367,1-48.
61. Wadenberg, M.L.,Soliman, A.,VanderSpek, S.C.,Kapur, S.(2001).Dopamine D (2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects.Neuropsychopharmacology,25,633-641.
62. Wieczorek, W.J.,Kruk, Z.L.(1994).Differential action of (+)-amphetamine on electrically evoked dopamine overflows in rat brain slices containing corpus striatum and nucleus accumbens.Br. J. Pharmacol.,111,829-836.
63. Yan, Q.S.,Yan, S.E.(2001).Activation of 5-HT (1B/1D) receptors in the mesolimbic dopamine system increases dopamine release from the nucleus accumbens: a microdialysis study.Eur. J. Pharmacol.,418,55-64.